Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
A prospective, single-center, single-blinded study involving patients with refractory
nontuberculous mycobacteria lung disease to ascertain pharmacokinetics, safety, efficacy, and
tolerability of two dose levels of parenteral administration of recombinant Interleukin-7
(IL-7) (CYT107).